DAILYPEPTIDE GUIDE
Clinical Pipeline

Survodutide

BI 456906

Survodutide is a clinical-stage asset. Trial status and sponsor-reported findings remain time-sensitive and indication-specific.

Compare
EvidenceTier 2
RegulatoryInvestigational
SafetyKnown but Manageable Risks
Clinical phasePhase 3
01

Overview

ClassDual glucagon/GLP-1 receptor agonist
Sponsor / developerBoehringer Ingelheim / Zealand Pharma
Review statusDraft
Record IDPEP-021
02

Plain-language guide

What it was designed or studied for

Designed for research into Obesity, MASH, Metabolic disease. It remains investigational for these uses.

How it works, simply

It copies a gut-hormone signal that helps the brain register fullness, slows stomach emptying and supports blood-sugar control.

This simplified explanation is educational context, not a treatment recommendation or a substitute for the clinical evidence below.
03

Clinical mechanism

Activates glucagon and GLP-1 receptors.

Mechanism plausibility is not the same as demonstrated clinical benefit.
04

Applications

  • Obesity
  • MASH
  • Metabolic disease
05

Human evidence

Early or mid-stage human data exist, but confirmation, replication or long-term follow-up remains incomplete.

Tier 2
06

Preclinical evidence

Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.

06

Regulatory status

Investigational. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.

07

Safety

Known but Manageable Risks

  • Adverse effects vary by product and indication
  • Contraindications and interactions require label review
08

Interactions

Review the current product label and indication-specific literature for pharmacologic and absorption interactions.

09

Treatment pattern

Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.

10

Manufacturing and quality

Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.

12

Sources

  1. 01
    Primary regulatory record

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  2. 02
    Clinical trial registry

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  3. 03
    Peer-reviewed literature

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

13

Gaps and unverified claims

  • Long-term outcomes and real-world safety are not yet established.
  • Current phase and catalysts require primary-source confirmation.
14

Last reviewed

August 5, 2026 · Draft